IL95525A - Pharmaceutical preparations containing a combination of two different plasminogen activators - Google Patents

Pharmaceutical preparations containing a combination of two different plasminogen activators

Info

Publication number: IL95525A
Authority: IL; Israel
Prior art keywords: tpa; human; amino acids; acid sequence; amino acid
Prior art date: 1989-09-01

Application number

IL9552590A

Other languages

English (en)

Hebrew (he)

Other versions

IL95525A0 (en

Original Assignee

Ciba Geigy Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-01

Filing date

1990-08-30

Publication date

1995-03-30

1990-08-30 Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag

1991-06-30 Publication of IL95525A0 publication Critical patent/IL95525A0/xx

1995-03-30 Publication of IL95525A publication Critical patent/IL95525A/en

Links

108010001014 Plasminogen Activators Proteins 0.000 title claims abstract description 44
102000001938 Plasminogen Activators Human genes 0.000 title claims abstract description 44
229940127126 plasminogen activator Drugs 0.000 title claims abstract description 44
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
208000007536 Thrombosis Diseases 0.000 claims abstract description 20
150000001413 amino acids Chemical class 0.000 claims description 171
101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 claims description 78
101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 claims description 49
230000003197 catalytic effect Effects 0.000 claims description 38
238000011282 treatment Methods 0.000 claims description 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
201000010099 disease Diseases 0.000 claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
230000002195 synergetic effect Effects 0.000 claims description 4
208000001435 Thromboembolism Diseases 0.000 claims description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
208000010125 myocardial infarction Diseases 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
206010003210 Arteriosclerosis Diseases 0.000 claims description 2
208000005189 Embolism Diseases 0.000 claims description 2
206010047249 Venous thrombosis Diseases 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
206010008118 cerebral infarction Diseases 0.000 claims description 2
208000026106 cerebrovascular disease Diseases 0.000 claims description 2
230000002934 lysing effect Effects 0.000 claims description 2
230000002107 myocardial effect Effects 0.000 claims description 2
201000005060 thrombophlebitis Diseases 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 6
238000002560 therapeutic procedure Methods 0.000 abstract description 6
238000011321 prophylaxis Methods 0.000 abstract description 4
229940024606 amino acid Drugs 0.000 description 104
235000001014 amino acid Nutrition 0.000 description 104
240000004808 Saccharomyces cerevisiae Species 0.000 description 26
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 24
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
239000000203 mixture Substances 0.000 description 15
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 13
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 13
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 13
229920000053 polysorbate 80 Polymers 0.000 description 13
230000009471 action Effects 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
230000009089 cytolysis Effects 0.000 description 11
230000000694 effects Effects 0.000 description 10
239000003102 growth factor Substances 0.000 description 10
239000000872 buffer Substances 0.000 description 9
230000000295 complement effect Effects 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
239000012634 fragment Substances 0.000 description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
239000003527 fibrinolytic agent Substances 0.000 description 7
238000000034 method Methods 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
239000001488 sodium phosphate Substances 0.000 description 7
229910000162 sodium phosphate Inorganic materials 0.000 description 7
239000000243 solution Substances 0.000 description 7
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 7
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 6
102000013563 Acid Phosphatase Human genes 0.000 description 6
108010051457 Acid Phosphatase Proteins 0.000 description 6
102000009123 Fibrin Human genes 0.000 description 6
108010073385 Fibrin Proteins 0.000 description 6
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
102000013566 Plasminogen Human genes 0.000 description 6
108010051456 Plasminogen Proteins 0.000 description 6
229920002684 Sepharose Polymers 0.000 description 6
239000011324 bead Substances 0.000 description 6
229950003499 fibrin Drugs 0.000 description 6
230000003480 fibrinolytic effect Effects 0.000 description 6
239000002609 medium Substances 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
239000000725 suspension Substances 0.000 description 6
239000000654 additive Substances 0.000 description 5
230000000996 additive effect Effects 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
230000002537 thrombolytic effect Effects 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
125000000729 N-terminal amino-acid group Chemical group 0.000 description 4
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 4
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 4
239000008121 dextrose Substances 0.000 description 4
229940088598 enzyme Drugs 0.000 description 4
239000006167 equilibration buffer Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
229940012957 plasmin Drugs 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000012545 processing Methods 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
229960005356 urokinase Drugs 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010053567 Coagulopathies Diseases 0.000 description 3
108091026890 Coding region Proteins 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
102000012479 Serine Proteases Human genes 0.000 description 3
108010022999 Serine Proteases Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
230000004913 activation Effects 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000023555 blood coagulation Effects 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
238000000855 fermentation Methods 0.000 description 3
230000004151 fermentation Effects 0.000 description 3
239000008103 glucose Substances 0.000 description 3
238000002372 labelling Methods 0.000 description 3
244000005700 microbiome Species 0.000 description 3
238000011084 recovery Methods 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
238000005406 washing Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
102000010911 Enzyme Precursors Human genes 0.000 description 2
108010062466 Enzyme Precursors Proteins 0.000 description 2
241001131785 Escherichia coli HB101 Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000003024 amidolytic effect Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000013613 expression plasmid Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
229960002885 histidine Drugs 0.000 description 2
108700023876 human Y acceptor Proteins 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229910000160 potassium phosphate Inorganic materials 0.000 description 2
235000011009 potassium phosphates Nutrition 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
206010002199 Anaphylactic shock Diseases 0.000 description 1
WAEDSQFVZJUHLI-BYULHYEWSA-N Asp-Val-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O WAEDSQFVZJUHLI-BYULHYEWSA-N 0.000 description 1
102100021277 Beta-secretase 2 Human genes 0.000 description 1
101710150190 Beta-secretase 2 Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
101710117667 Constitutive acid phosphatase Proteins 0.000 description 1
LBOLGUYQEPZSKM-YUMQZZPRSA-N Cys-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CS)N LBOLGUYQEPZSKM-YUMQZZPRSA-N 0.000 description 1
DQGIAOGALAQBGK-BWBBJGPYSA-N Cys-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N)O DQGIAOGALAQBGK-BWBBJGPYSA-N 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
101100379080 Emericella variicolor andB gene Proteins 0.000 description 1
241000219769 Erythrina latissima Species 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
OLIFSFOFKGKIRH-WUJLRWPWSA-N Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CN OLIFSFOFKGKIRH-WUJLRWPWSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
108010065920 Insulin Lispro Proteins 0.000 description 1
208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
MYZMQWHPDAYKIE-SRVKXCTJSA-N Lys-Leu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O MYZMQWHPDAYKIE-SRVKXCTJSA-N 0.000 description 1
AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
OZILORBBPKKGRI-RYUDHWBXSA-N Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 OZILORBBPKKGRI-RYUDHWBXSA-N 0.000 description 1
FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010038563 Reocclusion Diseases 0.000 description 1
101710167911 Repressible acid phosphatase Proteins 0.000 description 1
101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
102100033571 Tissue-type plasminogen activator Human genes 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
ZSXJENBJGRHKIG-UWVGGRQHSA-N Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 ZSXJENBJGRHKIG-UWVGGRQHSA-N 0.000 description 1
102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 1
SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 1
239000012190 activator Substances 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
108010041407 alanylaspartic acid Proteins 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
239000003708 ampul Substances 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000013058 crude material Substances 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
108010089804 glycyl-threonine Proteins 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
229940106780 human fibrinogen Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
239000006151 minimal media Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
108010018625 phenylalanylarginine Proteins 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000033885 plasminogen activation Effects 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
239000000047 product Substances 0.000 description 1
108700042769 prolyl-leucyl-glycine Proteins 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229960003766 thrombin (human) Drugs 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

IL9552590A 1989-09-01 1990-08-30 Pharmaceutical preparations containing a combination of two different plasminogen activators IL95525A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB898919803A GB8919803D0 (en)	1989-09-01	1989-09-01	Pharmaceutical compositions

Publications (2)

Publication Number	Publication Date
IL95525A0 IL95525A0 (en)	1991-06-30
IL95525A true IL95525A (en)	1995-03-30

Family

ID=10662394

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9552590A IL95525A (en)	1989-09-01	1990-08-30	Pharmaceutical preparations containing a combination of two different plasminogen activators

Country Status (17)

Country	Link
US (1)	US5409700A (de)
EP (1)	EP0421918B1 (de)
JP (1)	JP2904893B2 (de)
KR (1)	KR910005882A (de)
AT (1)	ATE94407T1 (de)
AU (1)	AU627927B2 (de)
CA (1)	CA2024309C (de)
DD (1)	DD299155A5 (de)
DE (1)	DE69003342T2 (de)
DK (1)	DK0421918T3 (de)
ES (1)	ES2058871T3 (de)
GB (1)	GB8919803D0 (de)
IE (1)	IE63523B1 (de)
IL (1)	IL95525A (de)
NZ (1)	NZ235107A (de)
PT (1)	PT95159B (de)
ZA (1)	ZA906957B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5994309A (en) *	1997-07-25	1999-11-30	Angstrom Pharmaceuticals, Inc.	Anti-invasive and anti-angiogenic compositions and methods
AU781023B2 (en) *	1999-11-04	2005-04-28	Genentech Inc.	Reversed-phase HPLC assay for plasminogen activators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL8503097A (nl) *	1985-11-11	1987-06-01	Leuven Res & Dev Vzw	Geneesmiddel met thrombolytische werking.
NL8601240A (nl) *	1986-05-15	1987-12-01	Leuven Res & Dev Vzw	Plasminogeenactivator en trombolytisch geneesmiddel.
FI100106B (fi) *	1986-12-05	1997-09-30	Novartis Ag	Menetelmä plasminogeenin yksisäikeisen yhdistelmäaktivaattorin valmist amiseksi
SE462829B (sv) *	1989-01-10	1990-09-10	Kabigen Ab	Trombolytiskt aktiva kompositioner innehaallande en modifierad plasminogenaktivator av vaevnadstyp samt en normal human t-pa, streptokinas eller humant urokinas

1989
- 1989-09-01 GB GB898919803A patent/GB8919803D0/en active Pending
1990
- 1990-08-23 EP EP90810639A patent/EP0421918B1/de not_active Expired - Lifetime
- 1990-08-23 DE DE90810639T patent/DE69003342T2/de not_active Expired - Fee Related
- 1990-08-23 DK DK90810639.6T patent/DK0421918T3/da active
- 1990-08-23 ES ES90810639T patent/ES2058871T3/es not_active Expired - Lifetime
- 1990-08-23 AT AT90810639T patent/ATE94407T1/de not_active IP Right Cessation
- 1990-08-27 DD DD90343663A patent/DD299155A5/de not_active IP Right Cessation
- 1990-08-30 IL IL9552590A patent/IL95525A/en not_active IP Right Cessation
- 1990-08-30 CA CA002024309A patent/CA2024309C/en not_active Expired - Fee Related
- 1990-08-30 NZ NZ235107A patent/NZ235107A/en unknown
- 1990-08-30 PT PT95159A patent/PT95159B/pt not_active IP Right Cessation
- 1990-08-31 IE IE317990A patent/IE63523B1/en not_active IP Right Cessation
- 1990-08-31 AU AU62053/90A patent/AU627927B2/en not_active Ceased
- 1990-08-31 ZA ZA906957A patent/ZA906957B/xx unknown
- 1990-08-31 JP JP2228484A patent/JP2904893B2/ja not_active Expired - Fee Related
- 1990-08-31 KR KR1019900013840A patent/KR910005882A/ko not_active Ceased
1993
- 1993-04-07 US US08/044,563 patent/US5409700A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2904893B2 (ja)	1999-06-14
PT95159B (pt)	1997-08-29
ATE94407T1 (de)	1993-10-15
EP0421918B1 (de)	1993-09-15
CA2024309C (en)	2003-05-27
KR910005882A (ko)	1991-04-27
DK0421918T3 (da)	1993-11-15
DE69003342D1 (de)	1993-10-21
IL95525A0 (en)	1991-06-30
CA2024309A1 (en)	1991-03-02
DD299155A5 (de)	1992-04-02
NZ235107A (en)	1992-07-28
AU6205390A (en)	1991-03-07
GB8919803D0 (en)	1989-10-18
ES2058871T3 (es)	1994-11-01
IE63523B1 (en)	1995-05-03
EP0421918A1 (de)	1991-04-10
ZA906957B (en)	1991-06-26
US5409700A (en)	1995-04-25
PT95159A (pt)	1991-05-22
IE903179A1 (en)	1991-03-13
JPH03130231A (ja)	1991-06-04
AU627927B2 (en)	1992-09-03
DE69003342T2 (de)	1994-02-24

Legal Events

Date	Code	Title
1996-10-31	FF	Patent granted
1998-02-08	HC	Change of name of proprietor(s)
2000-10-31	KB	Patent renewed
2004-11-10	KB	Patent renewed
2009-09-15	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
EP0196920B1 (de)	1994-07-06	Degradierte Spezies eines Gewebeplasminogenaktivators, pharmazeutische Zubereitung und Verfahren zur Herstellung derselben
EP0155387B1 (de)	1989-09-06	Fibrinolytisches hybrides Protein, Verfahren zu seiner Herstellung und pharmazeutische Zubereitung
JP2559538B2 (ja)	1996-12-04	組織プラスミノーゲン活性化因子の誘導体
US5830849A (en)	1998-11-03	Vampire bat salivary plasminogen activators
EP0751785A1 (de)	1997-01-08	Zusammensetzungen aus einer thrombolytisch wirkende substanz und antikoagulantien, und ihre verwendungen
JP2003514790A (ja)	2003-04-22	可逆的に不活性化された酸性化プラスミンの局所送達による血栓溶解の方法
JP2764264B2 (ja)	1998-06-11	線溶活性増強剤
EP0307847B1 (de)	1992-12-02	Thrombolytisches Agens
US5681721A (en)	1997-10-28	Bifunctional urokinase variants with improved fibrinolytic characteristics and thrombin inhibiting effect
AU603062B2 (en)	1990-11-08	Novel tissue plasminogen activator derivatives
AU627927B2 (en)	1992-09-03	Pharmaceutical compositions
PT98823A (pt)	1992-07-31	Processo para a preparacao de um activador de plasminogenio hibrido
US5234686A (en)	1993-08-10	Human tissue plasminogen activator consisting essentially of t-PA residues to 160 to 527, pharmaceutical compositions and methods of treatment
NZ257175A (en)	1996-07-26	Thrombin activated plasminogen derivatives with the cleavage site p4-p3-pro-arg-p1'-p2'
US5908625A (en)	1999-06-01	Use of the protease domain of human plasminogen activator for the treatment of thromboembolic diseases
WO1992018139A1 (en)	1992-10-29	Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques
JP2000504941A (ja)	2000-04-25	トロンビンによって活性化され得るプラスミノーゲンアクチベーター
US6682733B1 (en)	2004-01-27	Fibrinolytic enzymes
EP0796323A1 (de)	1997-09-24	Verwendung der proteasedomäne humanes gewebsplasminakilivators für die behandlung von thromboembolischen erkrankungen
Lin et al.	1987	Expression of human factor IX in mammalian cells
Finke et al.	1987	MYOCARDIAL SALVAGE BY COMBINED TREATMENT WITH RECOMBINANT SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN ACTIVATOR AND RECOMBINANT HUMAN SUPEROXIDE DISMUTASE IN A CANINE CORONARY THROMBOSIS MODEL
Berkner et al.	1987	EXPRESSION IN MAMMALIAN CELLS OF FUSION PROTEINS BETWEEN HUMAN FACTORS IX AND VII
JPH0775580A (ja)	1995-03-20	新規なｔ−ＰＡ改変体
MXPA99000966A (en)	1999-09-20	Plasminogen activator capable of being activated by thrombin